Indobufen

Why does isolated inhibition of thromboxane synthase not work?

For a long time, pharmacology attempted to create an antiplatelet agent with the most targeted action possible. One of the approaches was the isolated inhibition of the thromboxane synthase enzyme. The essence of this method was to block exclusively the synthesis of thromboxane $A_2$ without affecting the activity of cyclooxygenase (COX) at all.

However, in practice, this approach proved ineffective. The reason for failure lies in the specifics of the biochemical cascade. When the terminal enzyme is blocked, there is a massive accumulation of its direct substrate — cyclic endoperoxides. It turned out that these endoperoxides possess similar pharmacodynamic activity: much like thromboxane itself, they are capable of directly stimulating thromboxane receptors on platelet membranes. As a result of this substitution, the antiplatelet effect is completely negated.

Mechanism of action of indobufen

The drug indobufen (trade name — Ibustrin) represents a successful implementation of the combined inhibition concept. Its mechanism of action allows it to bypass the problem of active substrate accumulation. Indobufen blocks two critically important enzymes simultaneously:

• Thromboxane synthase (reduces the production of thromboxane $A_2$).
• Cyclooxygenase (prevents excessive formation of cyclic endoperoxides).

The key difference between indobufen and classical acetylsalicylic acid (ASA) lies in the nature of the interaction with the enzymes. While ASA shuts down COX permanently, indobufen causes reversible inhibition of cyclooxygenase.

The biochemical effect of the drug is manifested in a sharp decrease in the synthesis of thromboxane $A_2$. Simultaneously, a relative increase in the level of prostacyclin $I_2$ is observed. As a result, the prostacyclin/thromboxane ratio shifts in a favorable direction, providing reliable protection against thrombosis.

Pharmacodynamics and clinical effects

The pharmacodynamics of indobufen is not limited to mere interference with eicosanoid synthesis. The drug exerts a multifaceted effect on the hemostatic system:

1. Effectively inhibits platelet adhesion to the damaged vascular wall.
2. Suppresses the release reaction of proaggregatory factors from platelet granules.
3. Inhibits platelet aggregation (clumping) itself.

In addition to its effect on platelets, indobufen helps improve blood rheology. This is achieved by increasing erythrocyte deformability — red blood cells become more pliable and pass more easily through the narrow capillaries of the microvasculature.

Interestingly, the drug possesses anti-inflammatory and analgesic activity, which aligns it with the effects of ASA. However, the safety profile of indobufen looks more favorable: clinical data show that the risk of developing dangerous bleeding during its use is significantly lower than with acetylsalicylic acid therapy.

Alternative pathway: receptor blockade

An alternative and very modern approach to suppressing thromboxane activity is the direct blockade of its receptors. A prominent representative of this group is the drug terutroban (Terutroban, trade name — Triplion).

Its mechanism of action is fundamentally different: terutroban acts as a reversible thromboxane $A_2$ receptor antagonist. It does not interfere with enzyme function, but simply blocks the receptors on the platelet surface. This prevents platelet activation caused not only by thromboxane itself, but also by any other eicosanoids, including those very cyclic endoperoxides. In modern pharmacology, terutroban is considered the most promising drug in this group of antiplatelet agents.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Isolated inhibition of thromboxane synthase: biochemical reasons for pharmacological failure.
• The role of cyclic endoperoxides in platelet activation.
• Comparative characteristics of indobufen and acetylsalicylic acid.
• The effect of antiplatelet agents on blood rheological properties and erythrocyte deformability.
• Terutroban and the prospects of using thromboxane receptor antagonists.

Other topics in the section "Drugs affecting hemostasis and thrombosis"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.